search
Back to results

Effects of Weight Loss Management on Cognitive Function in Elderly Women With Obesity

Primary Purpose

Obesity, Cognitive Change

Status
Recruiting
Phase
Not Applicable
Locations
Russian Federation
Study Type
Interventional
Intervention
"PanTrek"
Physical Trainings
Placebo
Diet
Sponsored by
Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Obesity focused on measuring Elderly, Obesity, Weight loss, Cognitive Change, Exogenous Ketones, Diet, Physical activity

Eligibility Criteria

60 Years - 75 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria: Female; Age 60 and over; BMI 30.0 kg/m2 or more. Exclusion Criteria: Male; age under 60; BMI <30.0 kg/m2; patients unable or unwilling to comply with the requirements of the protocol, including the signing of informed consent (inability to give such consent due to mental deficiency or language barrier), as well as non-compliance with the schedule of visits, persons unable to independently make a decision and sign an informed consent; less than 6 months after suffering cardiovascular events, stroke, severe surgical interventions and injuries; alcohol abuse (including chronic pancreatitis of alcoholic etiology) or drug addiction at present or within the last 5 years; history of malignant diseases, regardless of the treatment during the last 5 years; less than 4 weeks after suffering acute infectious and / or inflammatory diseases, after the onset of complete clinical and laboratory remission; pregnancy and lactation; history of allergic reactions to components of the study product and/or placebo or intolerance to components of the study product and/or placebo.

Sites / Locations

  • Nutrition Clinic of the Federal Research Centre of Nutrition, Biotechnology and Food SafetyRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Active Comparator

Placebo Comparator

Active Comparator

No Intervention

Arm Label

The Product Group

The Combined Intervention Group

The Placebo Group

The Diet Group

The Control Group

Arm Description

The Product group is prescribed with the investigated product - exogeneous ketone bodies.

The Combined Intervention Group is prescribed with the investigated product -in combination with regular physical trainings.

The Placebo Group is prescribed with the Placebo.

The Diet Group is prescribed with the Diet designed with 500 kcal reduction from daily energy expenditure.

The Control Group is prescribed with standard recommendations for weight loss.

Outcomes

Primary Outcome Measures

Change from baseline body weight at 12 weeks
The dynamics of body weight
Change from baseline Montreal Cognitive Assessment (MoCa) test scores at 12 weeks
The changes in the cognitive testing results
Change from baseline Trail Making Test (TMT) a&b test scores at 12 weeks
The changes in the cognitive testing results (normal range - less than 78 and 273 seconds (=scores)).
Change from baseline Word recall test scores at 12 weeks
The changes in the cognitive testing results (normal range as 45 words (=scores) and more out of 5 repetitions). Minimal - 0 (worse result), maximal score - 50 (excellent result).
Change from baseline Mean response time in the test "Schulte tables" at 12 weeks
The changes in the cognitive testing results
Change from baseline The Stroop Color and Word Test results at 12 weeks
The changes in the cognitive testing results
Change from baseline Verbal fluency test results at 12 weeks
The changes in the cognitive testing results

Secondary Outcome Measures

Change from baseline fat mass at 12 weeks
The changes in the fat mass according to the bioimpedance analysis
Change from baseline skeletal muscle mass at 12 weeks
The changes in the skeletal muscle mass according to the bioimpedance analysis
Change from baseline visceral fat at 12 weeks
The changes in visceral fat according to the bioimpedance analysis
Change from baseline total cholesterol serum levels at 12 weeks
The changes of total cholesterol serum levels
Change from baseline LDL-cholesterol serum levels at 12 weeks
The changes of LDL-cholesterol serum levels
Change from baseline HOMA-IR (homeostasis model assessment - insulin resistance) index at 12 weeks
The changes of HOMA-IR index
Change from baseline C-reactive protein (CRP) serum levels at 12 weeks
The changes of CRP serum levels
Change from baseline Tumor Necrosis Factor Alpha (TNFa) serum levels at 12 weeks
The changes of TNFa serum levels
Change from baseline systolic blood pressure (SBP) at 12 weeks
The changes of SBP
Change from baseline diastolic blood pressure (DBP) at 12 weeks
The changes of DBP
Change from baseline grip strength at 12 weeks
The changes of grip strength measured by grip dynamometer on the leading hand
Change from baseline Six Minute Walk Test distance at 12 weeks
The changes of Six Minute Walk Test results
Change from baseline Hamilton Anxiety Rating Scale at 12 weeks
The changes of Hamilton Anxiety Rating Scale results (normal range - 6 scores and less).
Change from baseline Hamilton Depression Rating Scale at 12 weeks
The changes of Hamilton Depression Rating Scale results (normal range - 7 scores and less).

Full Information

First Posted
April 10, 2023
Last Updated
May 4, 2023
Sponsor
Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology
Collaborators
Federal Stare Budgetary Scientific Institution, Mental Health Research Center
search

1. Study Identification

Unique Protocol Identification Number
NCT05841173
Brief Title
Effects of Weight Loss Management on Cognitive Function in Elderly Women With Obesity
Official Title
Effects of Weight Loss Management on Cognitive Function in Elderly Obese Women
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 9, 2022 (Actual)
Primary Completion Date
June 30, 2023 (Anticipated)
Study Completion Date
December 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Federal State Budgetary Scientific Institution "Federal Research Centre of Nutrition, Biotechnology
Collaborators
Federal Stare Budgetary Scientific Institution, Mental Health Research Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
According to studies, the risk of cerebrovascular disease and cognitive decline are associated with age-related changes. In addition, there is data suggesting a relationship between the progression of this pathology and the presence of obesity and associated metabolic disorders. According to to some research, weight loss associated with cognitive function decline. In this regard, the development of effective, applicable in real clinical practice methods of non-drug treatment and prevention of cerebrovascular disorders and age-related cognitive decline in people with obesity and metabolic disorders, who are at high risk, seems to be extremely relevant. The main goal of the study is to compare the effectiveness of various weight loss approaches and to study their effects on the cognitive functions of elderly obesity women.
Detailed Description
The high prevalence of comorbid pathology characterised the elderly and senile population. Particularly, comorbid condition is often based on obesity. Also, an important characteristic of the elderly and senile age is the development of age-related cognitive deficit and progressive decline in cognitive functions, that is detected in 60.8% of people over 65 years old in Russia according to the EVKALIPT study. The prevalence of obesity in the Russian population reaches 40% among the elderly population. According to studies, the presence of obesity is "paradoxically" associated with less progression of cognitive function loss, and the risk reduction in some populations reaches 40%. However, the sarcopenic obesity is an independent predictor of cognitive impairment in the elderly. Consequently, the therapy of obesity in elderly and senile population faces two important aspects: the risk of muscle loss and the development of sarcopenia and progressive cognitive decline. The described features of this age group are consistent with the well-known "obesity paradox", in which overweight and obesity are associated with longer life expectancy. The risk of muscle mass reduction and cognitive functions decrease determines the formation of a specialised approach to obesity management in older population. Thus, the setting of softer and longer-term goals with a gradual decrease in body weight is typical. Studies have considered the use of various interventions, so far the combination of diet with exercise has proven effectiveness in muscle mass protection. At the same time, regular exercises reliably protect from cognitive decline. Thereby, the combination of diet and physical activity is considered as a suitable approach to obesity management in the elderly. Recently, there have also been a number of studies evaluating the effectiveness of the ketogenic diet. This diet pattern is reliably effective in body weight reduction, skeletal muscle mass maintenance, and adipose tissue metabolism improvement in the elderly . Also, the neuroprotective effects of the ketogenic diet have been confirmed by meta-analyses and have made it possible to include it in current guidelines for the prevention and treatment of cognitive impairment. However, the high frequency of negative effects and the associated low adherence limit the possibilities of using this diet, which led to the development of exogenous ketones that allow reaching the levels of blood ketone bodies associated with neuroprotective properties (0.2-0.5 mmol/l) with better portability. The main goal of the study is to compare the effectiveness of various weight loss approaches and to study their effects on the cognitive functions of elderly obesity women.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Cognitive Change
Keywords
Elderly, Obesity, Weight loss, Cognitive Change, Exogenous Ketones, Diet, Physical activity

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Prospective randomised parallel arms double control interventional study
Masking
ParticipantInvestigator
Masking Description
Masking is used between 2 groups out of 5 (between the Product group and Placebo group). The investigated product and Placebo have comparable organoleptic properties and are packed in the same containers labelled as N1 or N2. The participants are randomised for 5 arms. In the case of arms 1 and 2, they are prescribed to consume 2 doses of product per day without awareness of either it is the investigational product or a placebo (the investigational product or a placebo). Field investigators prescribe to participants product N1 or N2 according to group allocation without awareness of either it is the investigational product or a placebo.
Allocation
Randomized
Enrollment
200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
The Product Group
Arm Type
Experimental
Arm Description
The Product group is prescribed with the investigated product - exogeneous ketone bodies.
Arm Title
The Combined Intervention Group
Arm Type
Active Comparator
Arm Description
The Combined Intervention Group is prescribed with the investigated product -in combination with regular physical trainings.
Arm Title
The Placebo Group
Arm Type
Placebo Comparator
Arm Description
The Placebo Group is prescribed with the Placebo.
Arm Title
The Diet Group
Arm Type
Active Comparator
Arm Description
The Diet Group is prescribed with the Diet designed with 500 kcal reduction from daily energy expenditure.
Arm Title
The Control Group
Arm Type
No Intervention
Arm Description
The Control Group is prescribed with standard recommendations for weight loss.
Intervention Type
Dietary Supplement
Intervention Name(s)
"PanTrek"
Other Intervention Name(s)
Exogenous ketone bodies
Intervention Description
The intervention is represented by the investigational product "PanTrek", shots with liquid, 25 ml each (TU 10.89.19-01-44850857-2020). The composition of the product "PanTrek" (per 1 dose): Ginseng dry extract (Panax ginseng Meyer) all parts of the plant - 125 mg (the amount of ginsenosides in one vial is 9.0 mg ± 3.5 mg); Melissa officinalis dry extract (Melissa officinalis L) all parts of the plant - 340 mg (the amount of hydroxycinnamic acids is 19.50 mg / vial ± 10% in one vial); Apple juice concentrated 2.5% - 7,5 g; Potassium beta-hydroxybutyrate - 4,5 g; Magnesium beta-hydroxybutyrate - 500 mg; E211 sodium benzoate - no more than 5 mg; E202 Potassium sorbate - no more than 3,6 mg; Water purified - up to 25 ml. The product has registered as diet supplement in the Unified Register of Certificates of State Registration N RU.77.99.11.003.R.001152.04.21 from 05.04.2021.
Intervention Type
Behavioral
Intervention Name(s)
Physical Trainings
Other Intervention Name(s)
Exercises
Intervention Description
Physical activity is represented by 2 workouts lasting 45 minutes per week on an antigravity treadmill Alter-G M320 (AlterG, USA) and 2 sessions of reoxygenation lasting 30 minutes on a normobaric hypoxic therapy device ReOxy (Bitmos GmbH, Germany).
Intervention Type
Other
Intervention Name(s)
Placebo
Intervention Description
The placebo is represented by concentrated apple juice 2.5% - 7.5 g, potassium chloride - 2.405 g, MgCl2 - 0.382 g, sodium benzoate (E211) - 5 mg and potassium sorbate (E202) - 3.6 mg, brought to 25 ml of distilled water.
Intervention Type
Behavioral
Intervention Name(s)
Diet
Intervention Description
The studied diet is a low-calorie diet with an average energy value of 1730.16 kcal / day and a certain chemical composition (proteins - 108.80 g / day, fats - 68.10 g / day, carbohydrates - 162.60 g / day), including the main groups products (meat and poultry dishes, fish dishes, dairy products, cereals, vegetables and fruits). On average, 0.96-1.05 g of protein accounted for 1 kg of body weight of the subjects.
Primary Outcome Measure Information:
Title
Change from baseline body weight at 12 weeks
Description
The dynamics of body weight
Time Frame
Baseline (visit 1) and after 12 weeks (visit 2)
Title
Change from baseline Montreal Cognitive Assessment (MoCa) test scores at 12 weeks
Description
The changes in the cognitive testing results
Time Frame
Baseline (visit 1) and after 12 weeks (visit 2)
Title
Change from baseline Trail Making Test (TMT) a&b test scores at 12 weeks
Description
The changes in the cognitive testing results (normal range - less than 78 and 273 seconds (=scores)).
Time Frame
Baseline (visit 1) and after 12 weeks (visit 2)
Title
Change from baseline Word recall test scores at 12 weeks
Description
The changes in the cognitive testing results (normal range as 45 words (=scores) and more out of 5 repetitions). Minimal - 0 (worse result), maximal score - 50 (excellent result).
Time Frame
Baseline (visit 1) and after 12 weeks (visit 2)
Title
Change from baseline Mean response time in the test "Schulte tables" at 12 weeks
Description
The changes in the cognitive testing results
Time Frame
Baseline (visit 1) and after 12 weeks (visit 2)
Title
Change from baseline The Stroop Color and Word Test results at 12 weeks
Description
The changes in the cognitive testing results
Time Frame
Baseline (visit 1) and after 12 weeks (visit 2)
Title
Change from baseline Verbal fluency test results at 12 weeks
Description
The changes in the cognitive testing results
Time Frame
Baseline (visit 1) and after 12 weeks (visit 2)
Secondary Outcome Measure Information:
Title
Change from baseline fat mass at 12 weeks
Description
The changes in the fat mass according to the bioimpedance analysis
Time Frame
Baseline (visit 1) and after 12 weeks (visit 2)
Title
Change from baseline skeletal muscle mass at 12 weeks
Description
The changes in the skeletal muscle mass according to the bioimpedance analysis
Time Frame
Baseline (visit 1) and after 12 weeks (visit 2)
Title
Change from baseline visceral fat at 12 weeks
Description
The changes in visceral fat according to the bioimpedance analysis
Time Frame
Baseline (visit 1) and after 12 weeks (visit 2)
Title
Change from baseline total cholesterol serum levels at 12 weeks
Description
The changes of total cholesterol serum levels
Time Frame
Baseline (visit 1) and after 12 weeks (visit 2)
Title
Change from baseline LDL-cholesterol serum levels at 12 weeks
Description
The changes of LDL-cholesterol serum levels
Time Frame
Baseline (visit 1) and after 12 weeks (visit 2)
Title
Change from baseline HOMA-IR (homeostasis model assessment - insulin resistance) index at 12 weeks
Description
The changes of HOMA-IR index
Time Frame
Baseline (visit 1) and after 12 weeks (visit 2)
Title
Change from baseline C-reactive protein (CRP) serum levels at 12 weeks
Description
The changes of CRP serum levels
Time Frame
Baseline (visit 1) and after 12 weeks (visit 2)
Title
Change from baseline Tumor Necrosis Factor Alpha (TNFa) serum levels at 12 weeks
Description
The changes of TNFa serum levels
Time Frame
Baseline (visit 1) and after 12 weeks (visit 2)
Title
Change from baseline systolic blood pressure (SBP) at 12 weeks
Description
The changes of SBP
Time Frame
Baseline (visit 1) and after 12 weeks (visit 2)
Title
Change from baseline diastolic blood pressure (DBP) at 12 weeks
Description
The changes of DBP
Time Frame
Baseline (visit 1) and after 12 weeks (visit 2)
Title
Change from baseline grip strength at 12 weeks
Description
The changes of grip strength measured by grip dynamometer on the leading hand
Time Frame
Baseline (visit 1) and after 12 weeks (visit 2)
Title
Change from baseline Six Minute Walk Test distance at 12 weeks
Description
The changes of Six Minute Walk Test results
Time Frame
Baseline (visit 1) and after 12 weeks (visit 2)
Title
Change from baseline Hamilton Anxiety Rating Scale at 12 weeks
Description
The changes of Hamilton Anxiety Rating Scale results (normal range - 6 scores and less).
Time Frame
Baseline (visit 1) and after 12 weeks (visit 2)
Title
Change from baseline Hamilton Depression Rating Scale at 12 weeks
Description
The changes of Hamilton Depression Rating Scale results (normal range - 7 scores and less).
Time Frame
Baseline (visit 1) and after 12 weeks (visit 2)

10. Eligibility

Sex
Female
Gender Based
Yes
Gender Eligibility Description
The females participants are reqruited In order to reduce variability of results in the restricted sample size (40 person per group).
Minimum Age & Unit of Time
60 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Female; Age 60 and over; BMI 30.0 kg/m2 or more. Exclusion Criteria: Male; age under 60; BMI <30.0 kg/m2; patients unable or unwilling to comply with the requirements of the protocol, including the signing of informed consent (inability to give such consent due to mental deficiency or language barrier), as well as non-compliance with the schedule of visits, persons unable to independently make a decision and sign an informed consent; less than 6 months after suffering cardiovascular events, stroke, severe surgical interventions and injuries; alcohol abuse (including chronic pancreatitis of alcoholic etiology) or drug addiction at present or within the last 5 years; history of malignant diseases, regardless of the treatment during the last 5 years; less than 4 weeks after suffering acute infectious and / or inflammatory diseases, after the onset of complete clinical and laboratory remission; pregnancy and lactation; history of allergic reactions to components of the study product and/or placebo or intolerance to components of the study product and/or placebo.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yurgita R. Varaeva, MD, MRes
Phone
+79253841894
Email
YurgitaVaraeva@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Antonina V. Starodubova, MD, Full PhD
Phone
+79167470606
Email
avs.ion@yandex.ru
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Antonina V. Starodubova, MD, Full PhD
Organizational Affiliation
Deputy Director of the Federal Research Centre of Nutrition, Biotechnology and Food Safety
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Yurgita R. Varaeva, MD, MRes
Organizational Affiliation
Research Fellow of the Federal research Centre of Nutrition, Biotechnology and Food Safety
Official's Role
Principal Investigator
Facility Information:
Facility Name
Nutrition Clinic of the Federal Research Centre of Nutrition, Biotechnology and Food Safety
City
Moscow
ZIP/Postal Code
115446
Country
Russian Federation
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Antonina V. Starodubova, MD, Full PhD
Phone
0079167470606
Email
avs.ion@yandex.ru
First Name & Middle Initial & Last Name & Degree
Yurgita R. Varaeva, MD, MRes
Phone
0079253841894
Email
YurgitaVaraeva@gmail.com

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
32368021
Citation
Dadarlat-Pop A, Sitar-Taut A, Zdrenghea D, Caloian B, Tomoaia R, Pop D, Buzoianu A. Profile of Obesity and Comorbidities in Elderly Patients with Heart Failure. Clin Interv Aging. 2020 Apr 21;15:547-556. doi: 10.2147/CIA.S248158. eCollection 2020.
Results Reference
background
PubMed Identifier
34742925
Citation
Abdoli N, Salari N, Darvishi N, Jafarpour S, Solaymani M, Mohammadi M, Shohaimi S. The global prevalence of major depressive disorder (MDD) among the elderly: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2022 Jan;132:1067-1073. doi: 10.1016/j.neubiorev.2021.10.041. Epub 2021 Nov 4.
Results Reference
background
PubMed Identifier
36286917
Citation
Khovasova NO, Vorobyeva NM, Tkacheva ON, Kotovskaya YV, Naumov AV, Selezneva EV, Ovcharova LN. [The prevalence of anemia and its associations with other geriatric syndromes in subjects over 65 years old: data of Russian epidemiological study EVKALIPT]. Ter Arkh. 2022 Jan 15;94(1):24-31. doi: 10.26442/00403660.2022.01.201316. Russian.
Results Reference
background
PubMed Identifier
34264558
Citation
Martinchik AN, Laikam KE, Kozyreva NA, Keshabyants EE, Mikhailov NA, Baturin AK, Smirnova EA. [The prevalence of obesity in various socio-demographic groups of the population of Russia]. Vopr Pitan. 2021;90(3):67-76. doi: 10.33029/0042-8833-2021-90-3-67-76. Epub 2021 May 17. Russian.
Results Reference
background
PubMed Identifier
30863030
Citation
Hou Q, Guan Y, Yu W, Liu X, Wu L, Xiao M, Lu Y. Associations between obesity and cognitive impairment in the Chinese elderly: an observational study. Clin Interv Aging. 2019 Feb 15;14:367-373. doi: 10.2147/CIA.S192050. eCollection 2019.
Results Reference
background
PubMed Identifier
32019161
Citation
Vidyanti AN, Hardhantyo M, Wiratama BS, Prodjohardjono A, Hu CJ. Obesity Is Less Frequently Associated with Cognitive Impairment in Elderly Individuals: A Cross-Sectional Study in Yogyakarta, Indonesia. Nutrients. 2020 Jan 30;12(2):367. doi: 10.3390/nu12020367.
Results Reference
background
PubMed Identifier
30569063
Citation
Wang H, Hai S, Liu YX, Cao L, Liu Y, Liu P, Yang Y, Dong BR. Associations between Sarcopenic Obesity and Cognitive Impairment in Elderly Chinese Community-Dwelling Individuals. J Nutr Health Aging. 2019;23(1):14-20. doi: 10.1007/s12603-018-1088-3.
Results Reference
background
PubMed Identifier
34562568
Citation
Colleluori G, Villareal DT. Aging, obesity, sarcopenia and the effect of diet and exercise intervention. Exp Gerontol. 2021 Nov;155:111561. doi: 10.1016/j.exger.2021.111561. Epub 2021 Sep 23.
Results Reference
background
PubMed Identifier
31257976
Citation
Kokkinidis DG, Armstrong EJ, Giri J. Balancing Weight Loss and Sarcopenia in Elderly Patients With Peripheral Artery Disease. J Am Heart Assoc. 2019 Jul 2;8(13):e013200. doi: 10.1161/JAHA.119.013200. Epub 2019 Jun 29.
Results Reference
background
PubMed Identifier
31216732
Citation
Giudici KV, Guyonnet S, Rolland Y, Vellas B, de Souto Barreto P, Nourhashemi F; MAPT/DSA Group. Body Weight Variation Patterns as Predictors of Cognitive Decline over a 5 Year Follow-Up among Community-Dwelling Elderly (MAPT Study). Nutrients. 2019 Jun 18;11(6):1371. doi: 10.3390/nu11061371.
Results Reference
background
PubMed Identifier
31865598
Citation
Bosello O, Vanzo A. Obesity paradox and aging. Eat Weight Disord. 2021 Feb;26(1):27-35. doi: 10.1007/s40519-019-00815-4. Epub 2019 Dec 21.
Results Reference
background
PubMed Identifier
31286668
Citation
Semlitsch T, Stigler FL, Jeitler K, Horvath K, Siebenhofer A. Management of overweight and obesity in primary care-A systematic overview of international evidence-based guidelines. Obes Rev. 2019 Sep;20(9):1218-1230. doi: 10.1111/obr.12889. Epub 2019 Jul 8.
Results Reference
background
PubMed Identifier
31181771
Citation
Petroni ML, Caletti MT, Dalle Grave R, Bazzocchi A, Aparisi Gomez MP, Marchesini G. Prevention and Treatment of Sarcopenic Obesity in Women. Nutrients. 2019 Jun 8;11(6):1302. doi: 10.3390/nu11061302.
Results Reference
background
PubMed Identifier
31051329
Citation
Falck RS, Davis JC, Best JR, Crockett RA, Liu-Ambrose T. Impact of exercise training on physical and cognitive function among older adults: a systematic review and meta-analysis. Neurobiol Aging. 2019 Jul;79:119-130. doi: 10.1016/j.neurobiolaging.2019.03.007. Epub 2019 Mar 26.
Results Reference
background
PubMed Identifier
35276979
Citation
Ilyas Z, Perna S, A Alalwan T, Zahid MN, Spadaccini D, Gasparri C, Peroni G, Faragli A, Alogna A, La Porta E, Ali Redha A, Negro M, Cerullo G, D'Antona G, Rondanelli M. The Ketogenic Diet: Is It an Answer for Sarcopenic Obesity? Nutrients. 2022 Jan 30;14(3):620. doi: 10.3390/nu14030620.
Results Reference
background
PubMed Identifier
33336232
Citation
Buckinx F, Aubertin-Leheudre M. Nutrition to Prevent or Treat Cognitive Impairment in Older Adults: A GRADE Recommendation. J Prev Alzheimers Dis. 2021;8(1):110-116. doi: 10.14283/jpad.2020.40.
Results Reference
background
PubMed Identifier
31503023
Citation
McDonald TJW, Cervenka MC. Lessons learned from recent clinical trials of ketogenic diet therapies in adults. Curr Opin Clin Nutr Metab Care. 2019 Nov;22(6):418-424. doi: 10.1097/MCO.0000000000000596.
Results Reference
background

Learn more about this trial

Effects of Weight Loss Management on Cognitive Function in Elderly Women With Obesity

We'll reach out to this number within 24 hrs